CDK inhibitors: From the bench to clinical trials

Flavio Rizzolio, Tiziano Tuccinardi, Isabella Caligiuri, Chiara Lucchetti, Antonio Giordano

Research output: Contribution to journalArticle

Abstract

Cell cycle deregulation is one of the first steps that transform normal cells into tumor cells. CDKs are a family of proteins devoted to controlling cell cycle entry, progression and exit. Studies from animal models show a tissue-specific essentiality of the single CDKs. In cancer cells, mis-regulation of CDK function is a common event. For this reason the pioneer compound Flavopiridol was developed and many new drugs are currently under development. ATP and the last generation of non-ATP competitive inhibitors are now emerging as one of the most potentially powerful target therapies. Many clinical trials are ongoing, as either a single agent or in combination with the classical cytotoxic agents. In this review, we discuss new strategies and methods to design more potent, selective and specific CDK inhibitors, starting from evidence emerging from animal and cancer cell models.

Original languageEnglish
Pages (from-to)279-290
Number of pages12
JournalCurrent Drug Targets
Volume11
Issue number3
DOIs
Publication statusPublished - Mar 2010

Fingerprint

Cells
Clinical Trials
alvocidib
Cell Cycle
Animals
Neoplasms
Cytotoxins
Deregulation
Animal Models
Adenosine Triphosphate
Tumors
Tissue
Pharmaceutical Preparations
Proteins
Therapeutics

Keywords

  • CDK
  • CDK clinical trials
  • Kinase inhibitors

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Rizzolio, F., Tuccinardi, T., Caligiuri, I., Lucchetti, C., & Giordano, A. (2010). CDK inhibitors: From the bench to clinical trials. Current Drug Targets, 11(3), 279-290. https://doi.org/10.2174/138945010790711978

CDK inhibitors : From the bench to clinical trials. / Rizzolio, Flavio; Tuccinardi, Tiziano; Caligiuri, Isabella; Lucchetti, Chiara; Giordano, Antonio.

In: Current Drug Targets, Vol. 11, No. 3, 03.2010, p. 279-290.

Research output: Contribution to journalArticle

Rizzolio, F, Tuccinardi, T, Caligiuri, I, Lucchetti, C & Giordano, A 2010, 'CDK inhibitors: From the bench to clinical trials', Current Drug Targets, vol. 11, no. 3, pp. 279-290. https://doi.org/10.2174/138945010790711978
Rizzolio, Flavio ; Tuccinardi, Tiziano ; Caligiuri, Isabella ; Lucchetti, Chiara ; Giordano, Antonio. / CDK inhibitors : From the bench to clinical trials. In: Current Drug Targets. 2010 ; Vol. 11, No. 3. pp. 279-290.
@article{6b075d7ff4394fc9b725f72d9a4706e5,
title = "CDK inhibitors: From the bench to clinical trials",
abstract = "Cell cycle deregulation is one of the first steps that transform normal cells into tumor cells. CDKs are a family of proteins devoted to controlling cell cycle entry, progression and exit. Studies from animal models show a tissue-specific essentiality of the single CDKs. In cancer cells, mis-regulation of CDK function is a common event. For this reason the pioneer compound Flavopiridol was developed and many new drugs are currently under development. ATP and the last generation of non-ATP competitive inhibitors are now emerging as one of the most potentially powerful target therapies. Many clinical trials are ongoing, as either a single agent or in combination with the classical cytotoxic agents. In this review, we discuss new strategies and methods to design more potent, selective and specific CDK inhibitors, starting from evidence emerging from animal and cancer cell models.",
keywords = "CDK, CDK clinical trials, Kinase inhibitors",
author = "Flavio Rizzolio and Tiziano Tuccinardi and Isabella Caligiuri and Chiara Lucchetti and Antonio Giordano",
year = "2010",
month = "3",
doi = "10.2174/138945010790711978",
language = "English",
volume = "11",
pages = "279--290",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - CDK inhibitors

T2 - From the bench to clinical trials

AU - Rizzolio, Flavio

AU - Tuccinardi, Tiziano

AU - Caligiuri, Isabella

AU - Lucchetti, Chiara

AU - Giordano, Antonio

PY - 2010/3

Y1 - 2010/3

N2 - Cell cycle deregulation is one of the first steps that transform normal cells into tumor cells. CDKs are a family of proteins devoted to controlling cell cycle entry, progression and exit. Studies from animal models show a tissue-specific essentiality of the single CDKs. In cancer cells, mis-regulation of CDK function is a common event. For this reason the pioneer compound Flavopiridol was developed and many new drugs are currently under development. ATP and the last generation of non-ATP competitive inhibitors are now emerging as one of the most potentially powerful target therapies. Many clinical trials are ongoing, as either a single agent or in combination with the classical cytotoxic agents. In this review, we discuss new strategies and methods to design more potent, selective and specific CDK inhibitors, starting from evidence emerging from animal and cancer cell models.

AB - Cell cycle deregulation is one of the first steps that transform normal cells into tumor cells. CDKs are a family of proteins devoted to controlling cell cycle entry, progression and exit. Studies from animal models show a tissue-specific essentiality of the single CDKs. In cancer cells, mis-regulation of CDK function is a common event. For this reason the pioneer compound Flavopiridol was developed and many new drugs are currently under development. ATP and the last generation of non-ATP competitive inhibitors are now emerging as one of the most potentially powerful target therapies. Many clinical trials are ongoing, as either a single agent or in combination with the classical cytotoxic agents. In this review, we discuss new strategies and methods to design more potent, selective and specific CDK inhibitors, starting from evidence emerging from animal and cancer cell models.

KW - CDK

KW - CDK clinical trials

KW - Kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=77950837310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950837310&partnerID=8YFLogxK

U2 - 10.2174/138945010790711978

DO - 10.2174/138945010790711978

M3 - Article

C2 - 20210753

AN - SCOPUS:77950837310

VL - 11

SP - 279

EP - 290

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 3

ER -